subject area of
- A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer Academic Article
- A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia Academic Article
- A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172) Academic Article
- A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150 Academic Article
- Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group Academic Article
- Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group Academic Article
- Bortezomib in Multiple Myeloma: A Practice Guideline Academic Article
- Bortezomib in Relapsed or Refractory Waldenström's Macroglobulinemia Academic Article
- Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells Academic Article
- Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis Academic Article
- Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle Academic Article
- Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database Academic Article
- Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers Academic Article
- Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database Academic Article